Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness

Abstract

Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness J. Namkung1, Y.W. Kim1, J.Y. Kim2, H.B. Kim3, H.Y. Kim4, E.J. Park5, H.K. Sun6 1Department of Obstetrics and Gynecology 2Department of Pathology, The Catholic University of Korea, Seoul 3Department of Obstetrics and Gynecology, Hallym University College of Medicine, Seoul 4Department of Obstetrics and Gynecology, Busan; 5Department of Obstetrics and Gynecology, Eulji University. Seoul 6Kosin University Graduate School, Busan (Korea) Summary Purpose of Investigation: The aim of the current study is to assess the prognostic value of the lymphocyte-monocyte ratio (LMR) in patients with uterine sarcoma. Materials and Methods: The authors examined the LMR as a prognostic variable in a cohort of 66 patients with uterine sarcoma who underwent surgical resection. Patients were categorized into two groups based on the LMR using cut-off values determined by receiver operating characteristic curve (ROC) analysis. They assessed the effect of the LMR on progression-free survival (PFS) and validated the LMR as independent predictor of survival. Results: Using data from the whole cohort, the optimized LMR cut-off value selected using the ROC curve was 5.86 for PFS. The LMR-low and LMR-high groups included 45 (68.2%) and 21 (31.8%) patients, respectively. The five-year PFS rates in the LMR-low and LMR-high groups were 69.0% and 94.4%, respectively (p = 0.024). Via multivariate analysis, the authors identified FIGO stage, residual tumor after surgery, and LMR as the most valuable prognostic factors affecting PFS (p = 0.039, p = 0.018, and p = 0.043, respectively). Conclusion: The LMR is an independent prognostic factor affecting the PFS of patients with uterine sarcoma. Key words: Lymphocytes; Monocytes; Uterine neoplasms; Uterine sarcoma.